<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01355497</url>
  </required_header>
  <id_info>
    <org_study_id>G300505</org_study_id>
    <secondary_id>POWER2</secondary_id>
    <nct_id>NCT01355497</nct_id>
  </id_info>
  <brief_title>Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum</brief_title>
  <official_title>Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GTx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GTx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the investigational drug GTx-024 can help&#xD;
      patients with non small cell lung cancer increase physical function and maintain or gain&#xD;
      muscle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blind, placebo controlled, multicenter, multinational efficacy&#xD;
      and safety study in subjects with non small cell lung cancer. Subjects will be evenly&#xD;
      randomized to placebo or GTx-024 prior to initiation of first line chemotherapy. The primary&#xD;
      efficacy analysis will be based on total Lean Body Mass (LBM) and physical function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical Function</measure>
    <time_frame>Day 84</time_frame>
    <description>Measure is the percentage of subjects at day 84 with stair climb power change &gt;=10% from their baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lean Body Mass</measure>
    <time_frame>Day 84</time_frame>
    <description>Measure is the percentage of subjects at day 84 with lean body mass change &gt;=0% from their baseline value.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Muscle Wasting</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>GTx-024 3mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will be randomized to receive GTx-024 3mg sofgel capsule once daily for the duration of the trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects will be randomized to receive matching placebo once daily for the duration of the trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GTx-024</intervention_name>
    <description>subjects will be randomized to receive GTx-024 3mg softgel for the duration of the trial.</description>
    <arm_group_label>GTx-024 3mg once daily</arm_group_label>
    <other_name>enobosarm, ostarine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>subject will receive matching placebo for the duration of the trial</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  give voluntary, signed informed consent in accordance with institutional policies&#xD;
&#xD;
          -  be non-obese as defined as body mass index (BMI)&lt; or = 32 and weight &lt; 300 pounds (&lt;&#xD;
             136 kg)&#xD;
&#xD;
          -  have been diagnosed with Stage III or IV NSCLC&#xD;
&#xD;
          -  be prior to first line chemotherapy&#xD;
&#xD;
          -  planned first line chemotherapy regimen is platinum plus gemcitabine only or platinum&#xD;
             plus vinorelbine only or platinum plus pemetrexed only&#xD;
&#xD;
          -  if surgery is part of the cancer treatment, screening for this study should be&#xD;
             conducted at least 4 weeks (28 days) after surgery&#xD;
&#xD;
          -  life expectancy of &gt; 6 months&#xD;
&#xD;
          -  ECOG score &lt; or = 1&#xD;
&#xD;
          -  serum creatinine &lt; or = 2.0 mg/dL&#xD;
&#xD;
          -  MALES - age &gt; or = 30 years&#xD;
&#xD;
          -  - FEMALES - age &gt;or=30 years and clinically confirmed as postmenopausal.Subjects must&#xD;
             have undergone the onset of spontaneous or surgical menopause prior to the start of&#xD;
             this study. Spontaneous menopause is defined as the natural cessation of ovarian&#xD;
             function as indicated by being amenorrheic for at least 12 months. If the subject has&#xD;
             been amenorrheic for &gt;or=6 months but &lt;12 months they must have a serum FSH&#xD;
             concentration of &gt;or=50 mIU/mL and an estradiol concentration of &lt;or=25 pg/mL.&#xD;
             Surgical menopause is defined as bilateral oophorectomy.&#xD;
&#xD;
          -  MALES - subjects must agree to use a double barrier method of contraception during the&#xD;
             study and for 3 months after study completion. This may include the following: condom&#xD;
             + spermicide or condom + oral hormonal contraception&#xD;
&#xD;
          -  MALES - have a serum PSA of &lt; or = 4.0 ng/mL or a negative prostate biopsy (no&#xD;
             prostate cancer) within 6 months of evaluation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have, in the judgment of the Investigator, a clinically significant concurrent illness&#xD;
             or psychological, familial, sociological, geographical or other concomitant condition&#xD;
             that would not permit adequate follow-up and compliance with the study protocol&#xD;
&#xD;
          -  Have ALT/SGOT or AST/SGPT above 1.5 times the upper limit of normal (ULN) without&#xD;
             evidence of liver metastases and above 5 times the ULN in subjects with evidence of&#xD;
             liver metastases&#xD;
&#xD;
          -  have alkaline phosphatase greater than 3 times ULN and/or total bilirubin levels above&#xD;
             2 mg/dL at baseline&#xD;
&#xD;
          -  have biologic agents or kinase inhibitors as part of their first line chemotherapy&#xD;
             regimen including, but not limited to bevacizumab (Avastin), gefitinib (Nexavar) and&#xD;
             erlotinib (Tarceva)&#xD;
&#xD;
          -  cardiovascular: uncontrolled hypertension, congestive heart failure or angina&#xD;
&#xD;
          -  Pulmonary: Stage 4 chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  positive screen for Hepatitis B consisting of HBsAg (Hepatitis B Surface Antigen),&#xD;
             unless subject was diagnosed &gt; 10 years prior to enrollment and no evidence of active&#xD;
             liver disease&#xD;
&#xD;
          -  currently taking testosterone, oxandrolone (Oxandrin), testosterone-like agents (such&#xD;
             as dehydroepiandrosterone (DHEA), androstenedione, and other androgenic compounds&#xD;
             including herbals), or antiandrogens; previous therapy with testosterone and&#xD;
             testosterone-like agents is acceptable with a 30 day washout (if previous testosterone&#xD;
             therapy was long term depot within the past 6 months, the site should contact the&#xD;
             medical monitor for this study to determine appropriate washout period)&#xD;
&#xD;
          -  currently taking megestrol acetate (Megace), dronabinol (Marinol), medical marijuana&#xD;
             (medical cannabis) or any prescription medication intended to increase appetite or&#xD;
             treat unintentional weight loss&#xD;
&#xD;
          -  have a baseline stair climb time &gt;or=30 seconds (mean of two stair climbs)&#xD;
&#xD;
          -  have active cancer, other than NSCLC or non-melanoma carcinoma of the skin, within the&#xD;
             previous two years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Concord</city>
        <state>Massachusetts</state>
        <zip>01742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigator</name>
      <address>
        <city>Flat Rock</city>
        <state>North Carolina</state>
        <zip>28731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Canfield</city>
        <state>Ohio</state>
        <zip>44406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GTx Investigative Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>May 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2011</study_first_posted>
  <results_first_submitted>February 4, 2016</results_first_submitted>
  <results_first_submitted_qc>October 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2020</results_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GTx-024 3mg Once Daily</title>
          <description>subjects will be randomized to receive GTx-024 for the duration of the trial&#xD;
GTx-024: subjects will be randomized to receive GTx-024 for the duration of the trial.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>subjects will be randomized to matching placebo once daily for the duration of the trial&#xD;
placebo: subject will receive placebo for the duration of the trial</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other-not provided</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects included in the Full Analysis Set</population>
      <group_list>
        <group group_id="B1">
          <title>GTx-024</title>
          <description>subjects will be randomized to receive GTx-024 for the duration of the trail&#xD;
GTx-024: subjects will be randomized to receive GTx-024 for the duration of the trial.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>subjects will be randomized to receive placebo for the duration of the trial&#xD;
placebo: subject will receive placebo for the duration of the trial</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="159"/>
            <count group_id="B2" value="161"/>
            <count group_id="B3" value="320"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" lower_limit="41" upper_limit="79"/>
                    <measurement group_id="B2" value="62.0" lower_limit="40" upper_limit="81"/>
                    <measurement group_id="B3" value="61.0" lower_limit="40" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Physical Function</title>
        <description>Measure is the percentage of subjects at day 84 with stair climb power change &gt;=10% from their baseline value.</description>
        <time_frame>Day 84</time_frame>
        <population>Subjects included in the Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>GTx-024</title>
            <description>subjects will be randomized to receive GTx-024 for the duration of the trail&#xD;
GTx-024: subjects will be randomized to receive GTx-024 for the duration of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects will be randomized to receive placebo for the duration of the trial&#xD;
placebo: subject will receive placebo for the duration of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Function</title>
          <description>Measure is the percentage of subjects at day 84 with stair climb power change &gt;=10% from their baseline value.</description>
          <population>Subjects included in the Full Analysis Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="13.6" upper_limit="26.5"/>
                    <measurement group_id="O2" value="24.8" lower_limit="18.4" upper_limit="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lean Body Mass</title>
        <description>Measure is the percentage of subjects at day 84 with lean body mass change &gt;=0% from their baseline value.</description>
        <time_frame>Day 84</time_frame>
        <population>Subjects included in the Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>GTx-024</title>
            <description>subjects will be randomized to receive GTx-024 for the duration of the trail&#xD;
GTx-024: subjects will be randomized to receive GTx-024 for the duration of the trial.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects will be randomized to receive placebo for the duration of the trial&#xD;
placebo: subject will receive placebo for the duration of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>Lean Body Mass</title>
          <description>Measure is the percentage of subjects at day 84 with lean body mass change &gt;=0% from their baseline value.</description>
          <population>Subjects included in the Full Analysis Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="38.6" upper_limit="54.6"/>
                    <measurement group_id="O2" value="37.9" lower_limit="30.4" upper_limit="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 6 months</time_frame>
      <desc>Initiation: 29 Nov 2011, Completion: 30 May 2013</desc>
      <group_list>
        <group group_id="E1">
          <title>GTx-024 3mg Once Daily</title>
          <description>subjects will be randomized to receive GTx-024 for the duration of the trial&#xD;
GTx-024: subjects will be randomized to receive GTx-024 for the duration of the trial.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Once Daily</title>
          <description>subjects will be randomized to receive placebo for the duration of the trial&#xD;
placebo: subject will receive placebo for the duration of the trial</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Bone Marrow Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Hyperprothrombinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Thrombotic Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic Arteriovenous Malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate Antidiuretic Hormone Secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Erosive Duodentitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Gastric Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Mesentaric Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Condition Aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Liver Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Escherichia Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Infectious Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pneumonia Pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fractured Sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Blood Urea Increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases To Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Cancer Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Metastatic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Tumour Associated Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Tumour Compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Cognitive Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Loss Of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Neropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Optic Neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Superior Vena Cava Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="143" subjects_affected="84" subjects_at_risk="165"/>
                <counts group_id="E2" events="119" subjects_affected="79" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="92" subjects_affected="51" subjects_at_risk="165"/>
                <counts group_id="E2" events="114" subjects_affected="56" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="31" subjects_at_risk="165"/>
                <counts group_id="E2" events="55" subjects_affected="29" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="26" subjects_at_risk="165"/>
                <counts group_id="E2" events="52" subjects_affected="28" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="153" subjects_affected="74" subjects_at_risk="165"/>
                <counts group_id="E2" events="168" subjects_affected="73" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="81" subjects_affected="45" subjects_at_risk="165"/>
                <counts group_id="E2" events="82" subjects_affected="48" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="165"/>
                <counts group_id="E2" events="33" subjects_affected="25" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" events="34" subjects_affected="29" subjects_at_risk="165"/>
                <counts group_id="E2" events="36" subjects_affected="31" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="37" subjects_affected="26" subjects_at_risk="165"/>
                <counts group_id="E2" events="41" subjects_affected="29" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="25" subjects_at_risk="165"/>
                <counts group_id="E2" events="35" subjects_affected="27" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="165"/>
                <counts group_id="E2" events="29" subjects_affected="20" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="23" subjects_at_risk="165"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="165"/>
                <counts group_id="E2" events="37" subjects_affected="28" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="165"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="165"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="165"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="165"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="165"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Provide Sponsor with an advance copy of any proposed results communication at least 60 days prior to the date of the planned submission or presentation and Sponsor shall have 60 days from receipt to request any changes. Sponsor may request a delay of up to 60 additional days.&#xD;
The PI shall not present data until the earlier of Sponsor's publication of the results of all investigators participating in the Study or 18 months after completion of the Study at all participating sites.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, Clinical Operations</name_or_title>
      <organization>GTx Inc.</organization>
      <phone>1-901-261-3795</phone>
      <email>mdesordi@gtxinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

